| 1.5 0.11 (7.91%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.97 |
1-year : | 2.3 |
| Resists | First : | 1.69 |
Second : | 1.97 |
| Pivot price | 1.42  |
|||
| Supports | First : | 1.41 |
Second : | 1.25 |
| MAs | MA(5) : | 1.39 |
MA(20) : | 1.46 |
| MA(100) : | 1.56 |
MA(250) : | 2.94 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 44.9 |
D(3) : | 30.9 |
| RSI | RSI(14): 55.1 |
|||
| 52-week | High : | 9.21 | Low : | 0.98 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RPHM ] has closed below upper band by 11.2%. Bollinger Bands are 20.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.57 - 1.58 | 1.58 - 1.58 |
| Low: | 1.34 - 1.34 | 1.34 - 1.35 |
| Close: | 1.49 - 1.5 | 1.5 - 1.51 |
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Mon, 16 Sep 2024
Reneo Pharmaceuticals executive buys shares worth over $484k By Investing.com - Investing.com Australia
Fri, 13 Sep 2024
Reneo Pharmaceuticals Announces Merger and Executive Departure - TipRanks
Tue, 03 Sep 2024
RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders - Business Wire
Mon, 24 Jun 2024
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM - PR Newswire
Mon, 13 May 2024
Reneo Pharmaceuticals and OnKure Announce Proposed Merger - GlobeNewswire
Thu, 11 Jan 2024
symbol__ Stock Quote Price and Forecast - CNN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 5.1 (%) |
| Held by Institutions | 87.9 (%) |
| Shares Short | 3,230 (K) |
| Shares Short P.Month | 3,240 (K) |
| EPS | -1.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.29 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.8 % |
| Return on Equity (ttm) | -54 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -66 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -0.9 |
| PEG Ratio | 0 |
| Price to Book value | 0.65 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|